Authors
Virendra Singh, Souvik Ghosh, Baljinder Singh, Pradeep Kumar, Navneet Sharma, Ashish Bhalla, AK Sharma, NS Choudhary, Yogesh Chawla, CK Nain
Publication date
2012/6/1
Journal
Journal of hepatology
Volume
56
Issue
6
Pages
1293-1298
Publisher
Elsevier
Description
BACKGROUND & AIMS
Various vasoconstrictors are useful in the management of hepatorenal syndrome (HRS). Terlipressin is the drug of choice; however, it is expensive. In this study, we evaluated safety and efficacy of terlipressin and noradrenaline in the treatment of HRS.
METHODS
Forty-six patients with HRS type 1 were managed with terlipressin (group A, N=23) or noradrenaline (Group B, N=23) with albumin in a randomized controlled trial at a tertiary center.
RESULTS
HRS reversal could be achieved in 9 (39.1%) patients in group A and 10 (43.4%) patients in group B (p=0.764). Univariate analysis showed baseline Child Turcotte Pugh score (CTP), model of end stage liver disease (MELD), urine output on day 1(D1), albumin, and mean arterial pressure (MAP) were associated with response. However, on multivariate analysis only CTP score was associated with response. Fourteen patients in group A and …
Total citations
20122013201420152016201720182019202020212022202320247251439322138272822243215
Scholar articles